Molecule
Ganciclovir is a cytomegalovirus nucleoside analog DNA polymerase inhibitor indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. MedsAcross supplies Ganciclovir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZIRGAN is indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ZIRGAN is a nucleoside analog antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older.
Source: US FDA prescribing information
ZIRGAN is an antiviral drug.
Source: US FDA prescribing information
The recommended dosage is 1 drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals, and then 1 drop 3 times per day for 7 days. Apply 1 drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals, and then 1 drop 3 times per day for 7 days.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
ZIRGAN is indicated for topical ophthalmic use only. Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
Source: US FDA prescribing information
Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%). Most common adverse reactions were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
Source: US FDA prescribing information
Storage Store at 15°C to 25°C (59°F to 77°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Ganciclovir, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ganciclovir 500 mg/10 mL powder for injectionIntravenousGeneric name | — | US FDA | Available on request |
| Ganciclovir 500 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Zirgan 0.15% ophthalmic gelOphthalmic | Bausch & Lomb | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Ganciclovir in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Ganciclovir and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ganciclovir, including Zirgan.
Yes. The US FDA first approved Ganciclovir on 23 June 1989, according to Drugs@FDA.
No listed presentation of Ganciclovir is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Ganciclovir is classified under ATC code J05AB06 (Ganciclovir).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.